Try our Advanced Search for more refined results
Life Sciences
-
December 12, 2025
Fed. Circ. Says PTAB Was Right To Ax Tracking Patent Claims
The Federal Circuit on Friday refused to revive claims in a group of patents for tracking items during surgeries and other uses, rejecting challenges to how the Patent Trial and Appeal Board interpreted key claim terms.
-
December 12, 2025
Higgs Fletcher Forms White Collar, Regs Enforcement Team
San Diego-based law firm Higgs Fletcher & Mack LLP has launched a white collar crime and regulatory enforcement defense practice group, citing heightened regulatory scrutiny in the financial and healthcare sectors and rising enforcement risks for licensed professionals and institutions.
-
December 11, 2025
LA Bellwether Jury To Decide If J&J Hid Talc Risk For Decades
An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a California jury Thursday in a bellwether trial's closing arguments that the company hid the health risks of talc for decades, while the company's attorney insisted the science is on their side.
-
December 11, 2025
DC Circ. Oversees FDA Fight Over Generic IBS Drug
Norwich Pharmaceuticals faced off against the U.S. Food and Drug Administration before the D.C. Circuit twice Thursday morning, both battles part of the drugmaker's five-year effort to bring a generic version of a prescription antibiotic used to treat irritable bowel syndrome to market.
-
December 11, 2025
Tracking Challenges To USPTO's Discretion Policy
Leaders at the U.S. Patent and Trademark Office have significantly altered the Patent Trial and Appeal Board playing field since March, making changes to institution reviews that have led to unprecedented levels of petition denials. A steady stream of companies has challenged those changes through mandamus petitions to the Federal Circuit, and here Law360 tracks where those petitions stand.
-
December 11, 2025
Pharmacies Battle For Coverage Of Opioid Lawsuit Claims
Publix Super Markets and a Georgia-based generic-drug wholesaler urged the Eleventh Circuit on Thursday to force their insurers to defend them in numerous lawsuits accusing the pharmacies of improperly distributing opioids, arguing their policies' coverage for "bodily injury" should include the suits.
-
December 11, 2025
NC County Sues DuPont, 3M, Tyco Over PFAS Contamination
A county in southeastern North Carolina is suing 3M Co., DuPont de Nemours Inc., the Chemours Co., Tyco Fire Products LP and other companies, alleging that they knowingly sold products containing PFAS, or "forever chemicals," that have contaminated county land.
-
December 11, 2025
Elevance Health Adds Former Pfizer GC To Its Board
Insurer Elevance Health has appointed former Pfizer Inc. general counsel Amy Schulman, currently a managing partner of Polaris Partners, to serve on its board of directors.
-
December 11, 2025
Sidley Guides Diagnostic Imaging Firm Lumexa's $463M IPO
Private equity-backed diagnostic imaging provider Lumexa Imaging Holdings Inc., led by Sidley Austin LLP, began trading Thursday on the Nasdaq Global Select Market after pricing a $463 million initial public offering.
-
December 11, 2025
6th Circ. Panel Shows No Leanings On PBM Jurisdiction Fight
A Sixth Circuit appeals panel gave few hints Thursday on whether it would send back to state court a lawsuit from Ohio alleging that pharmacy benefit managers were driving up prescription prices through rebate schemes.
-
December 11, 2025
4 Firms Guide As Arcline Exits Medical Tech Co. In $685M Deal
Perimeter Solutions Inc. has agreed to acquire Medical Manufacturing Technologies LLC from Arcline Investment Management for approximately $685 million in cash, including certain tax benefits.
-
December 10, 2025
Diagnostic Co. Agrees To Oversight Reforms In Derivative Suit
A California federal judge has granted preliminary approval to a deal ending shareholder derivative claims that diagnostics company CareDx's executives and directors damaged the company by concealing its scheme to inflate its testing services revenue.
-
December 10, 2025
Teva Pulls 200 Patents From Orange Book Amid FTC Probe
The Federal Trade Commission said Wednesday an investigation it conducted into Teva Pharmaceuticals prompted the company to remove over 200 patents from the U.S. Food and Drug Administration's Orange Book.
-
December 10, 2025
Apple Tells Fed. Circ. ITC Move Boosts Watch Case Appeal
Apple Inc. has told the Federal Circuit that the U.S. International Trade Commission's decision last month to review whether a redesigned Apple Watch infringes Masimo Corp. patents "underscores the need" for the appeals court to reverse the ITC's original infringement finding.
-
December 10, 2025
Med Delivery Co. Fired Workers For Pay Complaints, Suit Says
A pharmaceutical delivery company misclassified drivers as independent contractors even though it controlled nearly every aspect of their work and fired 12 named drivers at once for speaking up about it, according to a proposed class action filed in Kentucky federal court.
-
December 10, 2025
Akerman Hires DOJ Civil Division Lawyer For Healthcare Team
Akerman LLP has brought on a former member of the U.S. Department of Justice's Civil Division, who will be joining the healthcare practice group as a partner in the firm's Washington, D.C., office, according to an announcement on Tuesday.
-
December 10, 2025
VC Apple Tree Hits Ch. 11 After Row With Russian Billionaire
Biotechnology investor Apple Tree Life Sciences Inc. and affiliates filed for Chapter 11 protection in Delaware bankruptcy court, days after a Chancery Court judge ordered a Russian billionaire who partnered with the fund to cough up $97 million that Apple Tree demanded to support its struggling medical companies.
-
December 10, 2025
Weil, Reed Smith Build WTW's Newfront Buy For Up To $1.3B
Advisory, brokerage and solutions company WTW, advised by Weil Gotshal & Manges LLP, announced Wednesday it had agreed to acquire Reed Smith LLP-led broker Newfront for up to $1.3 billion in a deal that will expand WTW's reach in the middle market and presence in technology, fintech and life sciences.
-
December 09, 2025
Generic-Drug Group Backs House Bill On Skinny Labels
An industry group representing the generic and biosimilar drug manufacturing sector has applauded the introduction of a U.S. House of Representatives bill titled The Skinny Labels, Big Savings Act, saying it will reduce prices across healthcare.
-
December 09, 2025
Conn. Seems Open To Limits On Drug Price Cap Enforcement
The state of Connecticut suggested Tuesday that drug sales to the state were not the same as drug sales "in this state" as defined by state law, a stance drug manufacturers promised to leverage in their efforts to block an impending drug price cap.
-
December 09, 2025
NJ Drugmaker, Chubb Settle $6.5M Defense Costs Suit
A New Jersey pharmaceutical company and Chubb have reached a settlement to end a lawsuit alleging the insurer owes nearly $6.5 million in outstanding legal fees stemming from a multibillion-dollar arbitration dispute over the development of a COVID-19 drug, according to a stipulation of dismissal from the companies.
-
December 09, 2025
Expert Invoices Discoverable In J&J Talc MDL, Judge Says
A New Jersey federal judge said Monday that the plaintiffs steering committee can receive invoices for Johnson & Johnson's experts' work relating to multidistrict litigation alleging the use of talcum powder caused ovarian cancer and mesothelioma, but only after it produces its own expert invoices.
-
December 09, 2025
Mistrial Declared In Fla. Opioid Case Against Pharmacies
A Florida state judge declared a mistrial following a hung jury after two weeks of deliberations in a lawsuit brought by hospitals alleging that Walmart, Walgreens and CVS pharmacies negligently doled out painkillers and contributed to the opioid crisis.
-
December 09, 2025
Hagens Berman's Novel DOJ Referral May Have Chilling Effect
A Pennsylvania federal judge's unusual decision to refer prominent plaintiffs firm Hagens Berman LLP to the U.S. Department of Justice for possible criminal investigation over its pursuit of claims related to morning sickness drug thalidomide could have a chilling effect on lawyers' advocacy, law professors and attorneys said.
-
December 09, 2025
Medical Appliance Co. Seeks Coverage For SEC Investigation
A Connecticut-based medical device technology company told a federal court that its insurer wrongfully denied coverage for an investigation by the Securities and Exchange Commission, alleging in a new lawsuit that the federal government's inquiry into the company's insured members triggered its directors and officers policy.
Editor's Picks
-
Supreme Court Will Tackle Patent Enablement In Amgen Case
The U.S. Supreme Court on Friday agreed to review Section 112 of the Patent Act for the second time in the law's history, accepting Amgen's request to consider how much a patent must disclose in order to meet enablement requirements.
-
A Circuit-By-Circuit Guide To FCA Suits After High Court Snub
The U.S. Supreme Court's refusal to resolve one of the False Claims Act's most consequential controversies leaves circuit courts deeply divided over whistleblower pleading obligations in ways that will reverberate nationwide, attorneys say. Here, Law360 explores each circuit's approach and scenarios that might finally trigger high court intervention.
-
Inside The Collapse Of A Pioneering Opioid Case For DOJ
The U.S. Department of Justice launched a "terribly flawed" criminal case against a drug distributor and several individuals amid pressure to alleviate Appalachia's opioid crisis, and a newly confirmed U.S. attorney displayed "courage and guts" by ending the case last month, defense counsel told Law360 in an expansive interview.
Expert Analysis
-
Series
Knitting Makes Me A Better Lawyer
Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.
-
How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation
On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.
-
Series
The Biz Court Digest: Welcome To Miami
After nearly 20 years in operation, the Miami Complex Business Litigation Division is a pioneer upon which other jurisdictions in the state have been modeled, adopting many innovations to keep its cases running more efficiently and staffing experienced judges who are accustomed to hearing business disputes, say attorneys at King & Spalding.
-
Identifying And Resolving Conflicts Among Class Members
As the Fifth Circuit's recent decision in Nova Scotia Health Employees' Pension Plan v. McDermott International illustrates, intraclass conflicts can determine the fate of a class action — and such conflicts can be surprisingly difficult to identify, says Andrew Faisman, a clerk at the U.S. District Court for the Southern District of New York.
-
Adapting To A Plaintiff-Side Mindset For Patent Monetization
A recent decrease in risk for patent owners at the U.S. Patent and Trademark Office, combined with increased corporate interest in monetizing patent assets, creates an attractive case for evaluating patents from a plaintiff-side mindset, but in-house counsel transitioning from a defense-side mindset to a plaintiff-side mindset should study certain considerations, says Kate Tellez at Steptoe.
-
AI Evidence Rule Tweaks Encourage Judicial Guardrails
Recent additions to a committee note on proposed Rule of Evidence 707 — governing evidence generated by artificial intelligence — seek to mitigate potential dangers that may arise once machine outputs are introduced at trial, encouraging judges to perform critical gatekeeping functions, say attorneys at Lankler Siffert & Wohl.
-
Series
The Law Firm Merger Diaries: Getting The Message Across
Communications and brand strategy during a law firm merger represent a crucial thread that runs through every stage of a combination and should include clear messaging, leverage modern marketing tools and embrace the chance to evolve, says Ashley Horne at Womble Bond.
-
Opinion
Horizontal Stare Decisis Should Not Be Casually Discarded
Eliminating the so-called law of the circuit doctrine — as recently proposed by a Fifth Circuit judge, echoing Justice Neil Gorsuch’s concurrence in Loper Bright — would undermine public confidence in the judiciary’s independence and create costly uncertainty for litigants, says Lawrence Bluestone at Genova Burns.
-
10 Commandments For Agentic AI Tools In The Legal Industry
Though agentic artificial intelligence has demonstrated significant promise for optimizing legal work, it presents numerous risks, so specific ethical obligations should be built into the knowledge base of every agentic AI tool used in the legal industry, says Steven Cordero at Akerman LLP.
-
Fed. Circ. In Oct.: Spotlight On Wording Beyond Patent Claims
The Federal Circuit's recent decision in Barrette Outdoor Living v. Fortress Iron provides useful guidance on how patent prosecutors should avoid language that triggers specification disclaimer and prosecution disclaimer, doctrines that may be used to narrow the scope of patent infringement claims, say attorneys at Knobbe Martens.
-
New Drug Ad Regs Could Lead To A Less Informed Public
A federal push to mandate full safety warnings in pharmaceutical advertising could make drug ads less appealing for companies to air, which in turn could negatively affect consumers' health decisions by removing an accessible information source, say Punam Keller at Dartmouth College and Ceren Canal Aruoba at Berkeley Research Group.
-
Series
Preaching Makes Me A Better Lawyer
Becoming a Gospel preacher has enhanced my success as a trial lawyer by teaching me the importance of credibility, relatability, persuasiveness and thorough preparation for my congregants, the same skills needed with judges and juries in the courtroom, says Reginald Harris at Stinson.
-
A Look At Middlemen Fees In 340B Drug Discount Program
A U.S. Senate committee's recent hearing on the Section 340B drug discount program, along with statistical analysis of payment amounts, contribute to a growing consensus that middlemen fees are too high, say William Sarraille at the University of Maryland, and Shanyue Zeng and Rory Martin at IQVIA.
-
How Large Patent Damages Awards Actually Play Out
Most large verdicts in patent infringement cases are often overturned or reduced on appeal, implying that the Federal Circuit is serving its intended purpose of correcting outlier outcomes, and that the figures that catch headlines and dominate policy debates may misrepresent economic realities, says Bowman Heiden at Berkeley School of Law.
-
Series
Law School's Missed Lessons: Practicing Client-Led Litigation
New litigators can better help their corporate clients achieve their overall objectives when they move beyond simply fighting for legal victory to a client-led approach that resolves the legal dispute while balancing the company's competing out-of-court priorities, says Chelsea Ireland at Cohen Ziffer.